01—Abstract
Summary
Summary of the 8-K filed March 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (ROIV) furnished a Form 8-K dated March 3, 2026, under Item 7.01 (Regulation FD Disclosure), attaching a press release issued by its subsidiary Priovant Therapeutics.
The release announces that the U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted it Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of calendar year 2026, and the company expects to launch the drug in the United States at the end of September 2026. The Priority Review designation was supported by the results of the Phase 3 VALOR study, which enrolled 241 subjects across 90 sites and is described as the longest and largest interventional DM trial to date and the first positive 52-week placebo-controlled study in DM.
Brepocitinib 30 mg met the primary endpoint of myositis Total Improvement Score (TIS) at Week 52 versus placebo and improved all nine Key Secondary endpoints. The release notes that serious infections increased on brepocitinib 30 mg compared with placebo, and that these events resolved with medical management in most cases.
The information is furnished rather than filed, so it is not subject to the liabilities of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act. The filing contains no financial statements or financial results.
02—Key points
Key Highlights
- FDA accepted the NDA for brepocitinib in dermatomyositis and granted Priority Review, which the release says is designed for medicines offering significant improvements in safety or effectiveness for serious conditions.
- PDUFA target action date assigned in the third quarter of calendar year 2026; the company expects a U.S. launch at the end of September 2026.
- Phase 3 VALOR study (N=241) met its primary endpoint at Week 52 for brepocitinib 30 mg versus placebo, described as the first positive 52-week placebo-controlled DM trial.
- Brepocitinib 30 mg improved all nine Key Secondary endpoints versus placebo, including skin disease, muscle disease and steroid sparing.
- More than two thirds of patients on brepocitinib 30 mg achieved TIS40, twice the minimum clinically important difference; more than half also reached steroid dependency of 2.5 mg/day or less.
- Serious infections were higher on brepocitinib 30 mg than placebo, per the release; the release states malignancy, cardiovascular and thromboembolic events were more frequent in the placebo arm.
- If approved, brepocitinib would be the first targeted therapy approved for dermatomyositis, per the release.
03—Questions
Frequently Asked Questions
What regulatory milestone did the FDA reach for brepocitinib?
The FDA accepted the New Drug Application for brepocitinib in dermatomyositis, filed by subsidiary Priovant Therapeutics, and granted it Priority Review.
When is the FDA decision expected and when would launch occur?
The FDA assigned a PDUFA target action date in the third quarter of calendar year 2026. The company expects to launch the drug in the United States at the end of September 2026.
What did the Phase 3 VALOR study show?
Brepocitinib 30 mg showed a statistically significant and clinically meaningful improvement versus placebo on the primary endpoint, myositis Total Improvement Score at Week 52, with benefit seen as early as Week 4. It also improved all nine Key Secondary endpoints.
What safety signals did the release disclose?
Serious infections were increased with brepocitinib 30 mg compared with placebo; the release says these resolved with medical management and treatment was completed in most cases. The release also says malignancy, cardiovascular and thromboembolic events occurred more frequently in the placebo arm.
Does this 8-K include financial results or guidance?
No. The filing furnishes a press release on the NDA acceptance and Priority Review under Item 7.01 and contains no financial statements, financial results or financial guidance. The information is furnished, not filed, for purposes of Section 18 of the Exchange Act.
04—Continue